Fosun Pharma Announces Conditional NMPA Approval of Axicabtagene Ciloleucel Injection for New Indication

Fosun Pharmaceutical announced on June 26 that the marketing registration application for Axicabtagene Ciloleucel Injection (trade name: Yikaida®) of Fosun Kite Biotechnology Co., Ltd. (As of the date of this announcement, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a holding subsidiary of the company, holds 50% equity interest) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are unresponsive to first-line immunochemotherapy or relapse within 12 months after first-line immunochemotherapy (referred to as "newly added indication") has recently been conditionally approved by the National Medical Products Administration.